Human Genome Epidemiology Literature Finder
|
Records 1 - 15 (of 15 Records) |
| Query Trace: Disease Progression and ERCC1[original query] |
|---|
| Influence of genetic markers on survival in non-small cell lung cancer. Drugs of today (Barcelona, Spain : 1998) 2003 Oct 39 (10): 775-86. Rosell Rafael, Taron Miquel, Camps Carlos, López-Vivanco Guiller |
| A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. British journal of cancer 2004 Jul 91 (2): 344-54. Stoehlmacher J, Park D J, Zhang W, Yang D, Groshen S, Zahedy S, Lenz H |
| ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Nov 25 (33): 5172-9. Smith Stephanie, Su Dan, Rigault de la Longrais Irene A, Schwartz Peter, Puopolo Manuela, Rutherford Thomas J, Mor Gil, Yu Herbert, Katsaros Dionyssi |
| The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer. Cancer chemotherapy and pharmacology 2010 Aug 66 (3): 493-500. Liang Jun, Jiang Tao, Yao Ru-yong, Liu Zi-min, Lv Hong-ying, Qi Wei-w |
| No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung cancer (Amsterdam, Netherlands) 2011 Jun 72 (3): 370-7. Yin Ming, Yan Jingrong, Voutsina Alexandra, Tibaldi Carmelo, Christiani David C, Heist Rebecca S, Rosell Rafael, Booton Richard, Wei Qing |
| Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study. Gynecologic oncology 2011 Jul 122 (1): 121-6. Krivak Thomas C, Darcy Kathleen M, Tian Chunqiao, Bookman Michael, Gallion Holly, Ambrosone Christine B, Deloia Julie |
| ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Mar 17 (6): 1632-40. Yin Ming, Yan Jingrong, Martinez-Balibrea Eva, Graziano Francesco, Lenz Heinz-Josef, Kim Hyo-Jin, Robert Jacques, Im Seock-Ah, Wang Wei-Shu, Etienne-Grimaldi Marie-Christine, Wei Qing |
| Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy. Pharmacogenomics 2012 Mar 13 (4): 419-27. Yan Li, Shu-Ying Yang, Shan Kang, Yip Benjamin H K, Rong-Miao Zhou, Na Wang, Hai-Yan S |
| Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study. Gynecologic oncology 2012 May 125 (2): 421-6. Rubatt Jennifer M, Darcy Kathleen M, Tian Chunqiao, Muggia Franco, Dhir Rajiv, Armstrong Deborah K, Bookman Michael A, Niedernhofer Laura J, Deloia Julie, Birrer Michael, Krivak Thomas Ca |
| Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients. Oncology reports 2013 Nov 30 (5): 2385-98. Mlak Rados?aw, Krawczyk Pawe?, Ramlau Rodryg, Kalinka-Warzocha Ewa, Wasylecka-Morawiec Maja, Wojas-Krawczyk Kamila, Kucharczyk Tomasz, Homa Iwona, Kozio? Piotr, Ciesielka Marzanna, Chudziak Dorota, Milanowski Janu |
| Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy. Cancer chemotherapy and pharmacology 2013 Aug 72 (2): 315-22. Chen Cui, Wang Fenghua, Wang Zhiqiang, Li Cong, Luo Huiyan, Liang Ying, An Xin, Shao Jianyong, Li Yuho |
| Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. Urologic oncology 2014 Jan 32 (1): 31.e25-33. Vaishampayan Ulka N, Fontana Joseph, Heilbrun Lance K, Smith Daryn, Heath Elisabeth, Dickow Brenda, Figg William |
| Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients. Clinical lung cancer 2014 Nov 15 (6): 455-65. Powrózek Tomasz, Kowalski Dariusz M, Krawczyk Pawe?, Ramlau Rodryg, Kucharczyk Tomasz, Kalinka-Warzocha Ewa, Knetki-Wróblewska Magdalena, Winiarczyk Kinga, Dyszkiewicz Wojciech, Krzakowski Maciej, Milanowski Janu |
| DNA repair gene ERCC1 polymorphisms may contribute to the risk of glioma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014 May 35 (5): 4267-75. Yuan Guanqian, Gao Dandan, Ding Shaofeng, Tan J |
| Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy. BMC cancer 2017 Jun 17 (1): 451. Karageorgopoulou Sofia, Kostakis Ioannis D, Gazouli Maria, Markaki Sonia, Papadimitriou Marios, Bournakis Evangelos, Dimopoulos Meletios-Athanassios, Papadimitriou Christos |
- Page last reviewed:Oct 1, 2023
- Page last updated:Dec 04, 2023
- Content source: